Acidification of synaptic vesicles by the vacuolar proton ATPase is essential for loading with neurotransmitter. Debated findings have suggested that V-ATPase membrane domain (V0) also contributes to Ca 2+ -dependent transmitter release via a direct role in vesicle membrane fusion, but the underlying mechanisms remain obscure. We now report a direct interaction between V0 c-subunit and the v-SNARE synaptobrevin, constituting a molecular link between the V-ATPase and SNARE-mediated fusion. Interaction domains were mapped to the membrane-proximal domain of VAMP2 and the cytosolic 3.4 loop of c-subunit. Acute perturbation of this interaction with c-subunit 3.4 loop peptides did not affect synaptic vesicle proton pump activity, but induced a substantial decrease in neurotransmitter release probability, inhibiting glutamatergic as well as cholinergic transmission in cortical slices and cultured sympathetic neurons, respectively. Thus, V-ATPase may ensure two independent functions: proton transport by a fully assembled V-ATPase and a role in SNARE-dependent exocytosis by the V0 sector.
INTRODUCTION
In nerve terminals, synaptic vesicles are loaded with neurotransmitters and dock at active zones. Through a process called priming they then acquire the ability to fuse and release their contents in response to Ca 2+ influx. It is largely admitted that Ca 2+ entry through voltage-gated channels is detected by the Ca 2+ sensor synaptotagmin that triggers the membrane fusion machinery (Sudhof, 2004) . A fusion pore connecting the vesicle lumen to the synaptic cleft opens and then expands, allowing neurotransmitters to diffuse into the synaptic cleft. In an alternative mode, the pore may close without expanding, resulting in transient or ''kiss and run'' release, which avoids vesicle collapse into the plasma membrane (He et al., 2006; Smith et al., 2008; Zhang et al., 2009 ). The implication of SNARE proteins in vesicular transport is ubiquitous in eukaryotes. Nerve terminals express the v-SNARE synaptobrevin (VAMP2), anchored in the synaptic vesicle membrane, and the t-SNAREs syntaxin 1 and SNAP-25, which are predominantly inserted in the plasma membrane. The assembly of synaptic SNARE complexes in a ''trans'' configuration between a docked synaptic vesicle membrane and the plasma membrane is a key process in membrane fusion. Deletions or mutations in synaptic SNARE proteins and their specific cleavage by clostridial neurotoxins have deleterious effects on synaptic neurotransmitter release (Jahn and Scheller, 2006; Sudhof, 2004) . It is generally accepted that SNAREs, assisted by the synaptotagmin, can directly drive lipid bilayer fusion, but the nature of the fusion pore is still a matter of debate and it seems likely that distinct modes of transmitter release reflect differences in the molecular organization of the membrane fusion machinery. The membrane-proximal part of the SNARE complex is thought to play an important role in membrane fusion. The C-terminal end of the SNARE complex can assemble and disassemble independently (Sorensen et al., 2006) . Introducing a linker at the VAMP2 juxtamembrane domain severely impairs evoked release (Deak et al., 2006; Bretou et al., 2008) , and the VAMP2 C-terminal unstructured segment W 89 -N 93 has been proposed to act as a SNARE complex folding arrest signal (Ellena et al., 2009) . In VAMP2, mutating the juxtamembrane tryptophans that are involved in interactions with calmodulin and lipids (Quetglas et al., 2000) increased spontaneous fusion and decreased evoked release in neurons (Maximov et al., 2009) , as well as reducing Ca 2+ -dependent exocytosis in PC12 cells (Quetglas et al., 2002) . Thus, full SNARE assembly might provide force to mix lipids mechanically or alternatively pin membranes together and provide scaffolding for proteins that act downstream to form a channel-like pore or catalyze rearrangements of lipid pore intermediates (reviewed in Chernomordik and Kozlov, 2008; Jackson and Chapman, 2008; Morel et al., 2001 ).
Several recent reports in different model systems implicate the multimolecular V0 domain of the vacuolar proton ATPase (V-ATPase) in membrane fusion (Hiesinger et al., 2005; Liegeois et al., 2006; Peters et al., 2001; Sun-Wada et al., 2006) . V-ATPase is a large enzymatic complex expressed in all eukaryotic cells, with the primary function of proton pumping. It is omnipresent in intracellular membrane compartments, including synaptic vesicles (Stevens and Forgac, 1997) , where it generates vesicular proton gradients and membrane potential that underlie GABA/monoamine and glutamate uptake (Moriyama et al., 1992) . V-ATPase is composed of two reversibly associated sectors, a peripheral multisubunit V1 sector that hydrolyses ATP and a membrane V0 sector that translocates protons. In mammals, V0 is composed of a rotor of six subunits (5 c-subunits and 1 c 00 -subunit) and single copies of a-, d-, and e-subunits.
Almost two decades ago, studies on Torpedo c-subunit (also called V0 proteolipid or mediatophore) suggested that it forms a pore mediating acetylcholine release (reviewed in Morel et al., 2001) . Peters et al. (2001) later demonstrated a crucial role of V0 in yeast vacuolar fusion, downstream of SNARE complex assembly, possibly via pore formation. A recent unbiased genetic screen for synaptic malfunction in Drosophila has identified the ortholog of the a1-subunit of V0 as an essential component in synaptic vesicle fusion, also acting downstream of SNAREs (Hiesinger et al., 2005) . Moreover, independently from its proton transport function, a role of the V-ATPase V0 sector has recently been demonstrated in the apical secretion See also Figure S1 .
of Hedgehog-related proteins mediated by exosomes in C. elegans (Liegeois et al., 2006) , as well as insulin secretion in pancreatic b cells (Sun-Wada et al., 2006) and lysosome-phagosome fusion in zebrafish (Peri and Nusslein-Volhard, 2008 ). The precise molecular action of V0 in secretion/neurotransmitter release is not yet clear and thus its direct involvement remains a controversial issue. Although earlier biochemical approaches suggested that V-ATPase subunits and SNAREs (Bennett et al., 1992; Galli et al., 1996; O'Connor et al., 1993; Shiff et al., 1996) are associated in large protein complexes, evidence for direct and regulated interaction is still missing.
We have therefore explored molecular links between SNAREs and V-ATPase. Our results indicate direct binding of VAMP2 and V0 c-subunit, an interaction that is regulated by Ca 2+ /calmodulin. Mapping of the interaction domains and injection of a mimetic peptide showed that acute perturbation of the VAMP2 c-subunit complex inhibits both central glutamatergic and peripheral cholinergic neurotransmission.
RESULTS

VAMP2 Interacts with V0 c-Subunit
Yeast two-hybrid (Y2H) methods have not been widely used to probe interactions between proteins with transmembrane (TM) domains. However, detection of V0 c-subunit as a partner for b1 integrin (Skinner and Wildeman, 1999) and identification of a full-length (FL) syntaxin 1 clone in a screen via bSNAP as bait (O.E.F., unpublished results) encouraged us to pursue Y2H analysis of in vivo interactions between SNAREs and V0 subunits. Therefore, we used the LexA Y2H system to probe for binding between c-subunit and VAMP2.
Our results showed that c-subunit binds to VAMP2 via an interaction involving the C-terminal third of c-subunit, indicating that the cytoplasmically oriented loop 3.4 is very likely to constitute the VAMP2-binding domain ( Figure 1A ; Figure S1 available online). Control experiments confirmed robust binding of FL VAMP2 to syntaxin1 and homodimerization of FL VAMP2 ( Figure 1B) . Interestingly, FL VAMP2 displayed an interaction with c-subunit (Figure 1 ) whereas a VAMP2 construct lacking the TM (VAMP2-DTM) did not. Two explanations can be envisaged: (1) VAMP2 TM carries the c-subunit binding site or (2) VAMP2 TM is required to anchor VAMP2 in the yeast inner nuclear membrane nearby its tetraspan binding partner. To discriminate between these possibilities, we generated a VAMP2 construct in which the TM was replaced by that of the t-SNARE syntaxin1 (VAMP2-stxTM). VAMP2-stxTM interacted with c-subunit, whereas FL syntaxin1 did not (Figure 1B) . These results indicate that VAMP2 harbors a c-subunit binding site located outside of its TM. VAMP2 TM is thus not necessary for binding to c-subunit but confers transport of VAMP2 to the inner nuclear membrane where the interaction takes place. V0 c-subunit is an extremely hydrophobic protein with four TM domains connected by very short loops and discrete N and C termini. Analysis of native proteins was unsuccessful because both commercially available and specifically designed peptide antibodies against exposed conserved regions of V0 c-subunit failed to recognize rat proteins (data not shown). We therefore expressed GFP-tagged full-length c-subunit (E-c-2-155) in HEK293 cells. Pull-down assays detected the specific binding of multimeric forms of E-c-2-155 to bacterially expressed GST-VAMP2-2-92, the soluble cytoplasmic domain of VAMP (GVD), but not to GST, immobilized on glutathione beads (Figures S1B and S1C). These data indicate that c-subunit can associate with VAMP2 and that the TM region of VAMP is not necessary for interaction, consistent with Y2H data.
Because of limited expression yields in HEK293 and in order to address direct binding interactions, we produced bacterially expressed tagged recombinant c-subunit. Major toxicity was encountered when overexpressing c-subunit in E. coli, but was overcome by acidifying the culture medium. A specific protocol to express and purify HSV-tagged c-subunit was developed, which allowed the recovery of milligram amounts of otherwise insoluble fusion proteins (Figure 2A , left). The profile of c-2-155 expression in western blots showed, in addition to monomers and dimers, higher-molecular-weight c-subunit multimers that resisted dissociation by SDS. Pulldown experiments via purified recombinant c-subunit and immobilized GVD established a direct interaction (Figure 2A , right). Mapping of c-subunit interaction sites on VAMP2 indicated that only VAMP constructs containing the calmodulin (CaM) binding motif at amino acids 77-92 (Quetglas et al., 2000) bound to c-2-155 ( Figure 2B ). Furthermore, mutation of juxtamembrane tryptophans (W 89 W 90 ) known to be involved in CaM binding (Quetglas et al., 2002) completely abolished c-subunit binding ( Figure 2C ). To consolidate binding data, we used soluble His-tagged VAMP2-DTM (HVD) to displace c-subunit binding to immobilized GVD. As shown in Figure S2A , a 10-fold molar excess of His-VAMP2DTM (HVD) reduced c-subunit binding to background levels whereas HVDW 89,90 A had no effect. ELISA assays with biotinylated, wild-type, or mutated (W 89,90 A) VAMP2 peptides (amino acids 77-94) corroborated delimitation of the binding domain on VAMP2, as well as the importance of W 89, W 90 in c-subunit binding (not shown).
We also investigated the salt dependency of this interaction. Pull-down experiments shown in Figure S2B revealed that binding was promoted by increasing [NaCl] reaching a maximum at 300 mM, but decreased thereafter. This corroborates the importance of hydrophobic interactions, consistent with the observation that tryptophans are important determinants in c-subunit/VAMP2 binding.
In order to gain insight into the stoichiometry of c-subunit/ VAMP2 interaction, we performed pull-down experiments via a fixed amount of GVD on glutathione beads and increasing concentrations of c-subunit. Both flow through (FT) and bound c-subunit, monitored by western blotting (Figure S2C ), show that below equimolar concentrations, almost no c-subunit was detectable in FT. When concentrations superior to an equimolar ratio of c-subunit/VAMP2 were attained, significant amounts of c-subunit appeared in the FT and the c-subunit binding curved displayed an inflection consistent with saturation. These data suggest a binding stoichiometry of 1 c-subunit:1 VAMP2. Aggregation or multimerization of c-subunit at high concentrations probably underlies the nonsaturating component of binding.
Given that the CaM-binding domain of VAMP2 (aa 77-92), and in particular W 89 ,W 90 , are crucial for association with c-subunit, we addressed the potential regulation of this interaction by Ca 2+ /CaM. As shown in Figure 2D , ELISA assays via immobilized GVD indicated a >85% decrease in c-subunit binding in the presence of a large excess of CaM. Inhibition was dependent on CaM activation by Ca 2+ as shown by the fact that mutant calmodulin (Keen et al., 1999 ) (CaM 1,2,3,4 ), with impaired Ca 2+ coordination in both N-and C-lobes, did not compete with c-subunit for binding to VAMP2. These results suggest that mutually exclusive binding of CaM or c-subunit to VAMP2 might be regulated by Ca 2+ signaling.
To dissect the VAMP2 binding site on c-subunit, following up on results obtained with Y2H, we used surface plasmon resonance (SPR) analysis. The recombinant C-terminal region of c-subunit, containing loop 3.4 (c-117-155) indicated highaffinity binding to HVD ( Figure 3A ). This interaction was completely abolished when loop 3.4 sequence was scrambled in the c-117-155-L3.4s construct. Analysis of binding data indicated a Kd = 1.9 ± 0.7 nM ( Figure S3A ). SPR data thus substantiated Y2H assays, underlining the importance of c-subunit loop 3.4 for binding to VAMP2.
In order to obtain a probe for functional experiments in neurons, we synthesized a peptide corresponding to c-subunit loop L3.4 (12 aa) and tested its capacity to interfere with c-subunit binding to VAMP2. 10 mM L3.4 inhibited GVD binding to immobilized full-length c-subunit by 36% in ELISA-based assays ( Figure 3B ) and by at least 47% in pull-down assays (not shown), reaching more than 60% in some experiments (Figure S3B) . In contrast, L3.4s did not inhibit binding in ELISA and inhibition reached only 10% in pull-down assays ( Figure S3B ).
We were also interested in determining whether the affinity of this sequence for its target was affected by its native topology in c-subunit, i.e., a short loop constrained by two flanking transmembrane anchors. We therefore inserted L3.4 peptide between the antiparallel b strands 6 and 6 0 of the cytohesin plextrin homology (PH) domain (Bedet et al., 2006) . This construct has been shown to scaffold an isolated protein sequence between two rigid structures, mimicking a loop inserted between two transmembrane domains (Bedet et al., 2006) . ELISA experiments with immobilized c-2-155 demonstrated that the constrained L3.4 sequence was approximately 10-fold more potent than the linear peptide ( Figure 3B ) in displacing the interaction with GVD. Pull-down assays ( Figure 3C ) on NiTA beads demonstrated that immobilized PH-L3.4 specifically bound GVD but not the W 89,90 P mutant. No binding was detected with PH-L3.4s. 10 mM of free synthetic L3.4 peptide inhibited this binding by more than 60% ( Figure 3C ).
All these experiments were performed with VAMP2 constructs devoid of its transmembrane domain and therefore do not predict whether L3.4 can bind to VAMP2 anchored in a lipid bilayer. Therefore, we reconstituted full-length VAMP2 in liposomes and tested its accessibility to L3.4. ELISA experiments showed that full-length wild-type VAMP2 proteoliposomes specifically bound to immobilized L3.4, but not L3.4s. Furthermore, binding was abrogated by W 89,90 A mutation in VAMP2 ( Figure S4A ). In addition, SPR data indicated that neither L3.4 nor L3.4s peptides interact directly with phospholipids (Figure S4B) . Altogether, these results indicate that synthetic L3.4 peptide, but not the scrambled sequence, effectively perturbs the interaction between c-subunit and VAMP2 and can be used to acutely probe its functional relevance by intraneuronal injection. 
L3.4 Peptide Decreases Release Probability in Connected L5-L5 Pyramidal Pairs
To address the physiological importance of the interaction, we examined the ability of L3,4 peptide to interfere with neurotransmitter release in acute rat cortical slices. Dual recordings from connected glutamatergic L5 pyramidal neurons (Figure 4A ; Debanne et al., 2008) were performed while injecting the synthetic L3.4 peptide or its scrambled sequence (L3.4s) into the presynaptic cell. Ten minutes after whole-cell access to the presynaptic neuron, EPSC amplitude slowly but robustly decreased and stabilized to 54.8% ± 8.5% (n = 7) of the control amplitude after 40 min ( Figure 4B ). In contrast, no reduction in amplitude occurred when the presynaptic pipette contained the scrambled L3.4 s peptide (103.7% ± 10.9%, n = 7; Figure 4C ). Although reduced transmitter release is likely to result from interference with the interaction between VAMP2 and c-subunit, an alternative possibility must be addressed. L3.4 peptide might interfere with intrinsic V-ATPase subunit interactions and inhibit proton pump activity. This could induce a default in vesicle loading with transmitter, leading to ''firing blanks'' (i.e., fusion of synaptic vesicles that are empty or have reduced contents). We therefore compared the effects on synaptic response amplitudes of a specific V-ATPase inhibitor bafilomycin A1, which induced a comparable reduction in EPSC (48.4% ± 5.6%; n = 7; Figure 4D ).
In order to rule out the possibility that the L3.4 peptide reduces release by inhibiting the proton pump, we compared its effect on release probability with that of bafilomycin A1. Although no change was observed in paired pulse ratio (PPR) in neurons injected with L3.4s peptide (97.7% ± 7.7%; n = 7; not shown), a decrease in release probability, translated by an increase in the paired pulse ratio (PPR), was observed in L3.4-injected neurons (152.0% ± 15.3% of the control PPR, n = 7; Figure 5A ). Importantly, the opposite effect was observed in bafilomycintreated neurons in which, in accordance with a previous report (Harrison and Jahr, 2003) , a decrease in PPR (74.9% ± 5.7% of the control, n = 7; Figure 5B ) was measured. This clearly demonstrates that the mechanisms underlying inhibition of neurotransmitter release by L3.4 and bafilomycin are distinct, suggesting that inhibition by L3.4 is likely to translate interference with the VAMP2/c-subunit interaction rather than proton pump inhibition. To directly address effects on proton pump activity, we performed in vitro assays with synaptic vesicle-enriched membrane fractions from rat brain. Intraluminal acidification by V-ATPase was triggered by addition of Mg 2+ /ATP and monitored fluorimetrically by acridine orange quenching. Results demonstrated that synaptic vesicle acidification was not affected at a concentration as high as 1 mM L3.4 peptide ( Figure 5D , left), although it was robustly inhibited by bafilomycin ( Figure 5D , right) or EDTA ( Figure S5 ). These data are consistent with the conclusion that inhibition of neurotransmitter release by L3.4 peptide entails decreased release probability and is not a consequence of suppressing proton transport.
L3.4 Peptide Inhibits Neurotransmitter Release in Cholinergic Rat Superior Cervical Ganglion Neurons
In order to ascertain whether v-SNARE interactions with V0 might constitute a general presynaptic mechanism, we also examined the action of L3.4 peptide at peripheral cholinergic synapses. Superior cervical ganglion (SCG) neurons provide a well-established culture system in which many agents that perturb neurotransmitter release mechanisms have been studied. Furthermore, unlike cortical neurons, SCG neurons have extremely short axons, and therefore somatically injected peptides reach nerve terminals very rapidly. Hence, this experimental system allows direct evaluation of the kinetics of effects, providing an indication as to which step in exocytosis is perturbed when a protein-protein interaction is disrupted (Ma and Mochida, 2007) . When L3.4 was injected into SCG neurons, inhibition started after around 1 min (1.1 ± 0.2 min, n = 6) ( Figures 6A and 6B) , reaching a plateau within 10 min (11.6 ± 2.4 min, n = 6), whereas See also Figure S5 .
Neuron V-ATPase and SNAREs in Neurotransmitter Release the scrambled peptide L3.4 s had no effect ( Figure 6B ). This rapid inhibition is comparable to that observed with agents that affect a late step in exocytosis (Mochida, 1998) . To corroborate these results, we injected a VAMP2 peptide (VAMP77-94) corresponding to the c-subunit binding site (aa 77-92) and a control peptide with the W 89,90 A mutation (VAMP77-94m) that abrogates binding to c-subunit. Wild-type VAMP2 peptide induced a very similar level of inhibition and onset to L3.4. VAMP77-94m like L3.4s had no effect on neurotransmission ( Figures 6B and 6C) . The time to peak of the decreased EPSP wave form was not affected by L3.4 ( Figure 6A1) ; however, the speed of rise to the peak ( Figure 6A2 ) and the decay from the peak were slightly slower ( Figure 6A3 ), suggesting that the kinetics of synaptic vesicle fusion might be modified in the presence of the peptide.
In agreement with experiments in cortical pairs, an effect of the peptide on proton pumping and thus on acetylcholine transport during vesicle recycling appears unlikely because the EPSP decrease was independent of stimulation frequency (synaptic activity) ( Figure 6C ; Ma and Mochida, 2007; Su et al., 2001) . Furthermore, in these strong peripheral synapses, inhibition by microinjected bafilomycin A1 displayed onset at around 40 min at 0.2 Hz ( Figure S6 ), which was very slow compared to that of L3.4 peptide at an even lower stimulation frequency ( Figure 6B ). In order to confirm that L3.4 did not interfere with the classical recycling pathway, reserve vesicles and the rapidly releasable vesicle pool were depleted by a 3 min train of presynaptic action potentials at 5 Hz (Lu et al., 2009; Ma and Mochida, 2007) and the recovery of EPSP amplitude was measured every 1 s. At the end of the train, the EPSP amplitude was within baseline noise levels ( Figures 6D-6F) , and subsequently recovered at two distinct fast and slow rates. L3.4 did not affect the recovery rates from synaptic vesicle depletion by either a 5 Hz train ( Figures 6D-6F ) or a 10 Hz train (data not shown). Together, these results consolidate data from L5-L5 synapses. Furthermore, they indicate that L3.4 peptide does not affect vesicle recycling and thus are consistent with the view that it perturbs the interaction of VAMP2 and c-subunit of V-ATPase V0 at a late step of exocytosis, close to fusion.
DISCUSSION
Analysis of links between SNAREs and V-ATPase subunits by Y2H, GST pull-down from lysates of transfected HEK293 cells, and direct binding studies with bacterially expressed proteins has uncovered a direct molecular interaction between the v-SNARE VAMP2 (synaptobrevin) and V0 c-subunit. The c-subunit binding domain on VAMP2 was mapped to the juxtamembrane region, which also constitutes a calmodulin-binding motif (Quetglas et al., 2000) . We delimited the VAMP2 binding site on c-subunit to the loop 3.4. Thus, the association occurs via two cytoplasmically oriented and membrane-proximal sequences, which is topologically consistent with a cis interaction between intrinsic vesicle membrane proteins. Dynamic regulation of this interaction is suggested by its displacement by Ca 2+ /CaM and by its dependence on the lipid environment. In fact, the presence of phosphatidylserine in VAMP2 liposomes inhibited L3.4 peptide binding (not shown). This is consistent with previous studies indicating that phosphatidylserine sequesters VAMP2 precluding SNARE assembly. The amphiphilic lipid sphingosine can displace phosphatidylserine and reactivate VAMP2 for exocytosis (Darios et al., 2009 ). It will be interesting to determine whether sphingosine also regulates interactions between VAMP2 and c-subunit.
In order to assess the functional relevance of this interaction, we chose acute peptide interference in synaptically coupled pairs of neurons. We measured neurotransmitter release by monitoring postsynaptic responses after presynaptic injection of the loop 3.4 peptide (L3.4) sequence in two different neuronal systems. This approach allowed us to analyze the kinetics of the onset of inhibition in a given pair and to determine whether effects occur during vesicle recycling or at later steps, close to fusion. Glutamatergic neurotransmission between two connected pairs of pyramidal neurones in acute cortical slices was robustly inhibited by loop 3.4 peptide injection whereas the scrambled peptide had no effect. Inhibition was not exclusive to glutamatergic synapses since cholinergic neurotransmission in SCG neuronal cultures was also inhibited, though to a lesser extent (22%) than in cortical neurons. Practically identical effects were observed upon injection of a VAMP2 peptide, corresponding to the juxtamembrane domain that binds L3.4. This result is consistent with the idea that both peptides act by disrupting the interaction between c-subunit and VAMP2. The difference in the extent of inhibition between cortical and SCG neurons may be due to the different mode of peptide injection. Peptide was transiently microinjected (3 min) into SCG neurons, whereas it diffused constantly into cortical neurons from a recording patch electrode.
Because L3.4 peptide mimics a c-subunit cytoplasmic linker sequence, we were concerned that it might modify intramolecular interactions between V-ATPase subunits and inhibit proton pumping, which would then compromise neurotransmitter loading into synaptic vesicles. In this case empty vesicles might still fuse without generating an EPSP, and therefore a reduced EPSP could result from blockade of the proton pump. Several observations allow us to rule out this possibility. First we compared the effects on neurotransmission of L3.4 peptide with those of bafilomycin A1, a specific inhibitor of the V-ATPase that blocks proton transport. In the strong synapses of peripheral SCG neurons, bafilomycin A1 modified EPSPs only after prolonged stimulation, whereas L3.4 peptide reduced EPSPs much more rapidly, even with lower stimulation frequencies. This observation is consistent with the idea that bafilomycin affects a step in vesicle recycling (e.g., reduced loading with transmitter resulting from a defective proton gradient) whereas L3.4 peptide inhibits a downstream step closer to vesicle fusion. As expected in the weaker synapses of central glutamatergic neurons, the onset of inhibition by bafilomycin was faster and induced gradual inhibition of EPSCs similar to that observed with L3.4. However, the effects of bafilomycin and L3.4 on short-term plasticity were completely different. L3.4 increased the paired pulse ratio (PPR) by more than 52% whereas bafilomycin produced the opposite effect with a PPR decrease of about 25%. Finally, high concentrations of L3.4 peptide had no effect on bafilomycin-sensitive proton transport by V-ATPase in vitro, in a membrane fraction enriched in synaptic vesicles. All these results indicate that the inhibition of neurotransmitter release by L3.4 peptide is not a consequence of perturbing V-ATPase proton pump activity. In addition, we demonstrated that L3.4 peptide had no affinity for lipids and thus is unlikely to perturb exocytosis by destabilizing membrane organization.
In SCG neurons, microinjected peptides reach nerve terminals very rapidly. The L3.4 as well as VAMP77-94 peptides induced prompt inhibition (onset at around 1 min), which is typical of agents that perturb neurotransmission at late steps in exocytosis (e.g., SNARE-interacting Synprint peptide from voltage-gated N-type calcium channel) (Mochida et al., 1996) , P/Q type calcium channel blockers (Mochida et al., 2003) . Consistent with this interpretation, the L3.4 peptide induced a slightly slower speed of rise and decay of the EPSP, suggesting that the kinetics of synaptic vesicle fusion might be modified in the presence of the peptide. Furthermore, experiments involving high-frequency stimulation and recovery, to examine whether L3.4 peptide perturbed the classical recycling pathway, indicated that it did not modify the refilling rate of the readily releasable or reserve vesicle pools. Hence, taken together, these results suggest that inhibition by L3.4 takes place at a step close to Ca 2+ triggering and fusion pore opening. Further investigation is, however, needed in order to precisely identify the molecular step at which L3.4 acts.
Therefore, our present data, obtained with the c-subunit domain that binds v-SNAREs as a probe, supports the hypothesis that V0 sector is involved in vesicle fusion. Published evidence also underlines the importance of the membrane-proximal partner sequence in VAMP2. VAMP2 W 89 W 90 residues are involved in binding Ca 2+ /CaM and acidic phospholipids (Quetglas et al., 2002) and contribute to SNARE complex dimerization (Fdez et al., 2008) . Interestingly, we now report that Ca 2+ /CaM inhibits c-subunit binding to VAMP2. Mutagenesis has underscored a role for juxta-membrane tryptophans in Ca 2+ -dependent exocytosis from PC12 cells (Quetglas et al., 2002) and neurons (Maximov et al., 2009) . Expression of the VAMP2 W 89,90 A mutant in VAMP2 KO neurons induced a 2-fold decrease in evoked release compared to wild-type rescue but did not affect SNARE assembly nor binding of complexin or synaptotagmin to the SNARE complex (Maximov et al., 2009) .
What might be the rationale for V0 c-subunit cooperation with SNARE proteins in neurotransmitter release? As yet we can only speculate. First, c-subunits might become available for VAMP2 binding only upon dissociation of the V1 sector, when optimal proton content and neurotransmitter transport into the vesicle have been achieved (Morel et al., 2003) . This could provide a regulatory link between vesicle filling and the later steps in exocytosis. Our previous work suggested that Ca 2+ /CaM competes with acidic phospholipids for binding to the membraneproximal region of VAMP2 and can switch interactions with lipids from cis to trans leaflets (de Haro et al., 2004 ). An extension to this hypothesis would be that a fraction of the VAMP2 molecules display cis interactions with c-subunits, rather than lipids, and these interactions arrest SNARE zippering. In this model, c-subunits might act in concert with the complexin accessory helix that mimes VAMP2 C-terminal domain and binds to t-SNAREs (Giraudo et al., 2009 ). Displacement of c-subunit by Ca 2+ /calmodulin could thus reactivate VAMP2 for completion of zippering. However, displacement appears to be inconsistent with the idea that VAMP2 is a scaffold positioning c-subunits for a role in membrane fusion. Could the V0 domain contribute to forming the fusion pore? Intriguingly, c-subunits purified from Torpedo (reviewed by Morel et al., 2001) or yeast (Peters et al., 2001 ) have been reported to form a regulated pore in vitro. Evidence from yeast led to the suggestion that SNARE pairing precedes the assembly of trans V0-V0 complexes that delineate a channel-like structure at the fusion site (Peters et al., 2001 ). However, yeast vacuolar fusion still occurs, although severely impaired, when V0 is present in only one of the two partner membranes destined to fuse (Bayer et al., 2003) . Further investigations in neurons, for example via point mutations that specifically affect a precise binary interaction, will be necessary to understand the precise role of c-subunit interaction with VAMP2 in neurotransmitter release and the mechanisms of its regulation by Ca 2+ /CaM.
EXPERIMENTAL PROCEDURES Reagents
All oligonucleotides were purchased from MWG Biotech (Germany). Yeast two-hybrid vectors and strains were purchased from OriGene Technologies, Inc. (Rockville, MD). Glutathione sepharose was from GE Healthcare and Ni-NTA agarose from QIAGEN. Lipids were from Avanti Polar Lipids. Peptides (L3.4: GVRGTAQQPRLF; L3.4s: GQATVQPLGRRF) were synthesized by Activotec (Southampton, UK) and (VAMP77-94: FETSAAKLKRKYWWKNLK; VAMP77-94m: FETSAAKLKRKYAAKNLK) by GenCust Europe (Luxembourg).
All protein purifications were performed in the presence of protease inhibitors (Complete, Roche).
Expression Constructs and Cloning Procedures
All sequences are from rat. For Y2H studies, VAMP2 constructs were either full length or contained syntaxin transmembrane domain VAMP2-STXTM. Except for two-hybrid studies where full-length VAMP2B was used, all VAMP2B constructs lacked a transmembrane domain (TM) (amino acids 2-92). All constructs were generated by standard polymerase chain reaction (PCR) via a commercial Y2H adult rat brain cDNA library (Origine). VAMP2 construct encompassing residues 2-92 (forward 5 0 -GCGAATTCTCGGCTACCGCTGC
was amplified and inserted between EcoR1 and Sal1 sites of pGEX4T-1 (GVD). One tenth of both purified newly generated fragments were mixed in the presence of Pfx and in the absence of additional primers or matrix and subjected to 10 cycles to generate the new mutated matrix. Primers 1 +4 were then added to the tube and cycling continued to amplify the full-length mutated construct. The consequent PCR product was digested with EcoR1 + Sal1 and ligated to pET28a-HSV-Nter. PH-L3.4 and PH-L3.4s were constructed as follows: with BbsI and SalI restriction sites, L3.4 and scrambled L3.4 s encoding phosphorylated complementary oligonucleotides were introduced between b strands 6 and 6 0 of the PH domain of human cytohesin1 in pET21d (Bedet et al., 2006 Yeast Two-Hybrid Analysis c-2-155 constructs were made in pGilda bait vector and VAMP2 in the prey vector pJG4-5. Lithium acetate was used to transform yeast cells (EGY48 strain) according to classical procedures. Binary interactions were probed by transforming bait and prey vectors into yeast cells containing the b-galactosidase encoding plasmid (pSH 18-34). To probe for protein interactions, transformants were plated on selection plates (-Ura, -Trp, -Leu, -His) containing X-gal.
Bacterial Protein Expression
VAMP2 and c-subunit were expressed in Rosetta2 bacteria (Novagen). VAMP2 constructs were expressed via classical protocols. Crude supernatants of ultracentrifuged ''French press'' bacterial lysates were stored at À20 C. Bacterial strains expressing c-subunit constructs were cultured in pH 5.7 phosphate-buffered LB medium and protein expression was induced with 1 mM IPTG for 4-5 hr. Bacterial pellets were stored at À20 C until protein purification. 2, 3, 4 were expressed in BL21.
Purification of His-HSV-Tagged c-Subunit Constructs
Ten grams of dry bacterial pellet were resuspended in 100 ml of buffer A (10 mM Tris-Cl, 100 mM NaH 2 PO 4 [pH 8.0], 500 mM NaCl, 6 M GuCl, 1% CHAPS [w/v], 20% glycerol, 20 mM imidazole, 10 mM b-mercaptoethanol).
The extract was sonicated to achieve complete homogenization and incubated overnight in the presence of DNase I (20 mg/ml) at 4 C with 2-3 ml of Ni-NTA beads (QIAGEN), prewashed with buffer A. Beads were then loaded in a column and subjected at gravity flow to successive washes with buffer A containing decreasing amounts of GuCl (4 M, 2 M, 0.5 M, 0 M). A last wash with buffer B (20 mM HEPES [pH 7.5], 150 mM NaCl, 0.5% CHAPS) was performed before collecting purified and renatured proteins by elution at 4 C in buffer B containing 250 mM imidazole. Protein concentration was determined with the micro BCA assay (Pierce) and eluted proteins were stored at À20 C in single-use aliquots.
Purification of GST and His-Tagged SNAREs
Bacterial pellets containing His-tagged proteins were French pressed in 20 mM Tris (pH 8.0), 500 mM NaCl, 10% glycerol buffer and purified on Ni-NTA beads. A last wash was made by adding to the French press buffer 50 mM imidazole and 0.5 mM DTT. Proteins were eluted in French press buffer containing 500 mM imidazole and 0.5 mM DTT and dialyzed overnight against 25 mM HEPES (pH 7.4), 140 mM KCl, and 0.5 mM DTT. Protein aliquots were stored at À80 C. Bacterial pellets of GST-tagged VAMP2-2-92 (GVD) and VAMP2-2-92-W 89,90 A (GV-W 89,90 A) were French pressed in 25 mM Tris (pH 8.0), 150 mM NaCl buffer and purified on glutathione Sepharose beads in the presence of 0.1% Triton X-100. Proteins were eluted in Tris 50 mM (pH 8.0), 10 mM reduced glutathione and frozen at À20 C until used. For full-length VAMP2 preparations, buffers were supplemented with 0.4% CHAPS.
Purification of Wild-Type and Mutant Calmodulin
Bacterial pellets containing GST-tagged proteins were French pressed in 25 mM Tris (pH 7.5), 150 mM NaCl. Fusion proteins were purified on glutathione-sepharose beads in the presence of Triton X-100. After washing with 25 mM Tris (pH 7.5), 150 mM NaCl, and 10 mM CaCl 2 , wild-type CaM and mutant CaM 1,2,3,4 were eluted by Thrombin and Factor Xa cleavage, respectively, according to the manufacturer's instructions. Proteins were dialyzed against HEPES 25 mM (pH 7.4), KCl 140 mM and stored at À20 C in 10%
glycerol.
Pull-Down Experiments
With standard procedures, VAMP2 constructs were freshly purified on glutathione beads from frozen cleared bacterial extracts. Per tube, a 1 ml mixture of 1 mM GST and GST-VAMP2 constructs (GVD, GV-2-31, GV-28-76, GV-28-92, GV-W 89,90 A, GV-W 89,90 P, or GV-W 90 A) was immobilized. For E-c-2-155, pretransfected HEK293 cells from a 10 cm culture dish were solubilized in 1 ml of 25 mM Tris (pH 7.5), 150 mM NaCl, 1% CHAPS supplemented with protease inhibitors (Complete, Roche). One-fifth of this extract was incubated with the corresponding preloaded glutathione bead pellet. For HSV-tagged c-2-155, 2-10 nM was added to the corresponding glutathione beads in 1 ml binding buffer: 25 mM Tris (pH 7.5), 150 mM NaCl, 0.5% CHAPS. For the salt sensitivity assay, 30 nM HSV-tagged c-2-155 was used in 25 mM Tris (pH 7.5), 0.5% CHAPS supplemented with the indicated concentrations of NaCl. Saturation studies were made with 1 mM GVD and indicated concentrations of HSV-tagged c-subunit. His-tagged HSV-c-2-155, PH-L3.4, or PH-L3.4s were freshly purified on Ni 2+ beads. Per tube, 100 nM purified GVD or GV-W 89,90 A was added in the presence of L3.4 or L3.4s (1 and 10 mM). In all conditions, incubation was overnight at 4 C. Beads were washed four times with binding buffer and bound proteins were eluted in SDS sample buffer. For saturation studies, supernatants were collected and TCA precipitated. Proteins were separated by SDS-PAGE and c-subunit binding to VAMP2 was probed by western blotting with either monoclonal anti-GFP (Roche) or polyclonal anti-HSV antibodies (AbCaM) (1:2500) and Immobilon western (Millipore) or super signal West pico (Pierce) HRP chemiluminescence substrates. GVD binding to immobilized c-2-155 or PH constructs was probed with goat polyclonal anti-GST antibodies (GE healthcare). Quantifications were carried out with ImageJ.
ELISA Nunc Maxisorp 96-well plates were coated overnight with L3.4 or L3.4s (10 mg/ml), purified GST, GVD, or His-HSV-c-2-155 (2 mg/ml) in 100 mM NaHCO 3 (pH 8.9) buffer. For His-HSV-c-2-155, after a 1 hr blocking step with 25 mM Tris (pH 7.5), 150 mM NaCl, 1% casein, 0.05% Tween 20, 300 nM GVD, or GV-W 89,90 P in 25 mM Tris (pH 7.5), 150 mM NaCl, 0.1% BSA, 0.05% Tween 20 was added in the presence or absence of increasing concentrations of L3.4 or L3.4 s peptides. GST and GVD-coated plates were blocked for 1 hr with 25 mM Tris (pH 7.5), 150 mM NaCl, 1% BSA, 0.05% Tween 20, 0.5% CHAPS. With the same buffer containing 0.5 mM CaCl 2 , the wells were incubated overnight with 30 nM HSV-c2-155 and purified recombinant CaM or CaM 1,2,3,4 . Wells coated with L3.4 and L3.4s were blocked for 2 hr at 37 C with 25 mM Tris (pH 7.5), 150 mM NaCl, 1% casein.
1 mM VAMP2-myc-his or VAMP2-W 89,90 A-myc-his liposomes were added to the wells in blocking buffer and incubated for 2 hr at 37 C. GVD, HSV-tagged c-2-155, and VAMP2-myc-his binding were probed with anti-GST (1:7500) (GE Healthcare), anti-HSV (AbCaM) (1:2500), or a monoclonal custom-made anti-VAMP2 antibody (GeneCust Europe, Luxembourg), respectively. The chromogenic HRP substrate TMB (3,3 0 ,5,5 0 -tetramethylbenzidine) was then used to detect the binding of HRP-coupled secondary antibodies (Jackson ImmunoResearch).
V-ATPase-Mediated Proton Uptake
The following protocol was inspired from Goncalves et al. (2000) with modifications: four rat brains were homogenized in 0.32 M sucrose, 10 mM HEPES-KOH, 0.2 mM EGTA in the presence of protease inhibitor cocktail (Sigma), then centrifuged for 10 min at 900 3 g. 3 ml of supernatant were layered onto a 4 ml 0.8 M sucrose cushion and centrifuged 20 min at 257,000 3 g. Synaptosome pellets were then resuspended in hypotonic buffer (10 mM Tris-HCl [pH 8.5], 1 mM PMSF) and centrifuged 20 min at 40,000 3 g. The synaptic vesicle-enriched supernatant was then adjusted to 10 mM TrisHCl (pH 8.5), 60 mM sucrose, 140 mM KCl, 2 mM MgCl 2 , 50 mM EGTA (assay buffer). ATP-dependent proton transport was monitored by the quenching of acridine orange (AO) fluorescence. When the synaptic vesicle lumen is acidified, membrane-permeable AO becomes protonated and trapped within the synaptic vesicle. The high AO concentration achieved results in a red-shift and self-quenching of fluorescence. In 100 ml final reaction buffer, a 5-fold dilution of enriched synaptic vesicle preparation was incubated at 30 C in the presence of 2 mM AO (Sigma). Proton uptake was triggered by adding 500 mM Mg-ATP. Experiments were carried out in Nunclon fluorescence plates with a Biotek Sirius HT injector plate reader and KC4 software. Fluorescence at 525 nm was monitored with data acquisition every 15 s.
Preparation of Liposomes and Proteoliposomes 850 nmoles of dried lipids were used in each case. To prepare protein-free liposomes, 85% mol/mol 1-palmitoyl, 2-oleoyl phosphatidylcholine + 15% 1,2-dioleoylphosphatidylserine were resuspended in 25 mM HEPES-KOH (pH 7.4), 140 mM KCl, 0.25 mM DTT, 1.5% (w/v) sodium cholate (Sigma). When preparing VAMP2-myc-his proteoliposomes, 1-palmitoyl, 2-oleoylphosphatidylcholine was resuspended as above in the presence of VAMP2 at a 1/100 (mol/mol) protein-to-lipid ratio. Liposomes and proteoliposomes were obtained by rapid dilution and extensive dialysis in the resuspension buffer without detergent.
Binding Analysis by SPR SPR experiments were conducted at 25 C with a Biacore 3000 (GE Healthcare). Purified HVD (2000-3000 resonance units [RU] ) was covalently coupled in 10 mM sodium acetate (pH 5) to a CM5 chip via amine group linkage with standard coupling procedures (Quetglas et al., 2002) . c-117-155 or c-117-155-L3.4s were injected at 30 ml/min with Kinject mode in HBS EP (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20) containing Triton X-100 0.005% as running buffer. All flow cells were regenerated for 40 s between samples with 50 mM octylglucoside diluted in running buffer. Data obtained over a nonfunctionalized flow cell were subtracted from all runs to account for nonspecific binding (less than 5% of total binding). Interactions were fitted globally across all concentrations to a 1:1 Langmuir binding model and rate constants were derived with BIA Evaluation 4.1 software. The affinity constant, K D , was calculated from the ratio of the rate constants kd (dissociation rate) versus ka (association rate). To measure peptide interactions with lipids, protein-free liposomes (PC or PS/PC) were immobilized on an L1 sensor chip to generate a stable lipid surface. PC liposomes were immobilized in the control flow cell and experiments were conducted as described (de Haro et al., 2004) with 16 mM NaOH for regeneration.
Preparation, Recording, and Data Analysis from Cortical Slices Cortical slices and dual whole-cell recordings were obtained as detailed previously (Boudkkazi et al., 2007) . Loop 3.4 (L3.4) or scrambled (L3.4s) synthetic c-subunit peptides were injected (2 mM) into the presynaptic neurons. Bafilomycin A1 was purchased from Euromedex (France) and was bath applied (final concentration, 5 mM). All paired-pulse protocols were performed at a frequency of 20 Hz. Synaptic responses were averaged according to alignment of the presynaptic action potentials with automatic peak detection (Detectivent 4.0, N. Ankri INSERM). Data are means ± SEM.
Synaptic Transmission from SCG Neurons 6-to 8-week cultures, EPSP recording, and injection of peptides (1.5 mM; 5 mM showed no further effect) were performed as described previously (Mochida et al., 1994) . EPSPs were recorded at 0.1, 0.25, or 0.5 Hz. The peak amplitudes were normalized to the values before injection. The averaged and smoothed values (Origin 7.5) obtained from an eight-point moving average algorithm were plotted against recording time with t = 0 corresponding to the start of 3 min presynaptic injection of L3.4, L3.4s (a scrambled control peptide). Data are mean ± SEM. A two-tailed Student's t test was applied as indicated.
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